NASDAQ:NAMS NewAmsterdam Pharma Q4 2025 Earnings Report $22.74 +0.06 (+0.26%) Closing price 04:00 PM EasternExtended Trading$22.60 -0.14 (-0.62%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast NewAmsterdam Pharma EPS ResultsActual EPS-$0.63Consensus EPS -$0.40Beat/MissMissed by -$0.23One Year Ago EPSN/ANewAmsterdam Pharma Revenue ResultsActual Revenue$0.19 millionExpected Revenue$0.92 millionBeat/MissMissed by -$730.00 thousandYoY Revenue GrowthN/ANewAmsterdam Pharma Announcement DetailsQuarterQ4 2025Date2/18/2026TimeBefore Market OpensConference Call DateWednesday, February 18, 2026Conference Call Time7:00AM ETUpcoming EarningsNewAmsterdam Pharma's Q3 2026 earnings is estimated for Wednesday, November 4, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K) NewAmsterdam Pharma Earnings HeadlinesAnalysts Are Bullish on Top Healthcare Stocks: PTC Therapeutics (PTCT), NewAmsterdam Pharma Company (NAMS)September 23 at 1:32 PM | theglobeandmail.comNewAmsterdam Pharma (NAMS) Wins EU Approvals. Can Cholesterol Pills Drive Royalties?September 22 at 10:51 PM | insidermonkey.comCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to trigger the next crash. The research firm Bernstein Research said this AI company has the power to crash the global economy for a decade, the CEO just issued a CODE RED in an internal memo warning employees they're dealing with a critical situation, and another company executive even implied they might need a government bailout. The last time I saw something like this was in 2008 when I predicted a stock market meltdown just three weeks before Lehman went under.September 24 at 1:00 AM | Paradigm Press (Ad)Analysts Have Conflicting Sentiments on These Healthcare Companies: NewAmsterdam Pharma Company (NAMS) and Lipocine (LPCN)September 22 at 7:21 PM | theglobeandmail.comNewamsterdam Pharma Company N.V. and Menarini Group Receive European Commission Approval for Ubeslo and EvlarcoSeptember 22 at 2:20 PM | marketscreener.comMNewAmsterdam Wins First Global Approval For Obicetrapib Cholesteorl TreatmentsSeptember 21 at 7:11 PM | rttnews.comSee More NewAmsterdam Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NewAmsterdam Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NewAmsterdam Pharma and other key companies, straight to your email. Email Address About NewAmsterdam PharmaNewAmsterdam Pharma (NASDAQ:NAMS) is a clinical-stage biopharmaceutical company focused on developing therapies for cardiometabolic diseases, particularly conditions involving elevated cholesterol and residual cardiovascular risk. The company’s lead product candidate is obicetrapib, an oral, low-dose cholesteryl ester transfer protein (CETP) inhibitor designed to reduce low-density lipoprotein cholesterol and improve other lipid parameters. Obicetrapib has been evaluated in several clinical studies, including the Phase 3 BROADWAY trial, for patients whose cholesterol levels remain inadequately controlled despite the use of existing lipid-lowering treatments. NewAmsterdam has also studied obicetrapib in combination with ezetimibe and in other patient populations. The company’s development strategy is centered on providing additional oral treatment options for people who remain at elevated cardiovascular risk. NewAmsterdam Pharma was formed in 2019 and became a publicly traded company in 2022 through a business combination with Frazier Lifesciences Acquisition Corporation. The company operates internationally, with activities spanning the United States and Europe, and is led by Chief Executive Officer Michael Davidson, M.D., a physician and biotechnology executive with experience in cardiovascular drug development.View NewAmsterdam Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Restaurant Stocks Near 52-Week Lows as Consumer Pressure BuildsPaychex Plunges, Providing the Entry Investors Have Been Waiting ForThe Case for Buying High-Yield General Mills Just StrengthenedEnergy Transfer Taps the AI Power BoomFull Throttle: Kratos and GE Fire Up a Next-Gen Defense EngineSandisk Joins the S&P 100—Is the Index Flow, or the AI Story, Driving the Stock? Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
